HOME >> BIOLOGY >> NEWS
Other highlights in the August 4 JNCI

ut its association with response to taxane-based chemotherapy is not clear. Dennis J. Slamon, M.D., Ph.D., of the University of California, Los Angeles, and colleagues analyzed retrospective data from a randomized clinical trial that had treated patients with metastatic breast cancer with either taxane-based epirubicinpaclitaxel (ET) chemotherapy or epirubicincyclophosphamide (EC) chemotherapy.

They found that HER-2/neu overexpression does not adversely influence response to first-line ET or EC chemotherapy and that a taxane-containing regimen, such as ET, may provide a preferential benefit to patients with tumors that overexpress HER-2/neu.

Contact: Kim Irwin, Women's Cancer Program Area, Jonsson Cancer Center, 310-206-2805, kirwin@mednet.ucla.edu

Researchers Examine Targeted Therapy for Neuroblastoma in Mouse Model

Survival is poor in patients with advanced-stage neuroblastoma, a cancer of nerve cells in infants and children, and there is a need to develop better treatments. Mirco Ponzoni, Ph.D., of G. Gaslini Children's Hospital in Genoa, Italy, and colleagues show that by encapsulating an antisense oligonucleotide targeting an oncogene and activating the innate immune system in a liposome that specifically targets neuroblastoma cells, neuroblastoma-bearing mice lived longer than mice given any other treatment in the study.

Contact: Mirco Ponzoni, G. Gaslini Children's Hospital, 39-010-563-6342, mircoponzoni@ospedale-gaslini.ge.it

Also in the August 4 JNCI:

  • No Survival Benefit for Adjuvant Chemotherapy for Colon Cancer after 10 Years:
    http://www.eurekalert.org/emb_releases/2004-08/jotn-acf072904.php
  • Activated Signaling Pathway May Predict Lung Cancer Patients' Response to Gefitinib:


  • Contact: Sarah L. Zielinski
    jncimedia@oupjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    3-Aug-2004


    Page: 1 2 3

    Related biology news :

    1. Other highlights in the September 1 JNCI
    2. Other highlights in the August 18 JNCI
    3. Other highlights in the July 7 JNCI
    4. Other highlights in the June 16 JNCI
    5. Other Highlights in the June 2 JNCI
    6. Other highlights in the May 19 JNCI
    7. Other highlights in the May 5 JNCI
    8. Other highlights of the March 17 issue of JNCI
    9. Other highlights in the March 3 issue of JNCI
    10. Other highlights in the February 18 issue of JNCI
    11. Other highlights in the February 4 issue of JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: Other highlights the August JNCI

    (Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
    (Date:4/23/2014)... biomedical engineer at the University of Houston (UH) is ... transfusions safer. His work is supported by a $1.8 ... , Blood transfusions save millions of lives every ... Without them, for instance, routine surgeries would become life ... strong evidence that transfusions of red blood cells stored ...
    (Date:4/22/2014)... to behave at the dinner tablecut up their food and ... Eating Behaviors , found that when 6-10 year old children ... such as drumsticks, whole apples, or corn on the cob ... cut. "They were twice as likely to disobey adults ... Professor and Director of the Cornell Food and Brand Lab. ...
    Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Biting vs. chewing 2
    (Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
    (Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
    (Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
    (Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
    Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
    Cached News: